BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34477373)

  • 1. Ruthenium(II) Diphosphine Complexes with Mercapto Ligands That Inhibit Topoisomerase IB and Suppress Tumor Growth In Vivo.
    da Silva MM; Ribeiro GH; de Camargo MS; Ferreira AG; Ribeiro L; Barbosa MIF; Deflon VM; Castelli S; Desideri A; Corrêa RS; Ribeiro AB; Nicolella HD; Ozelin SD; Tavares DC; Batista AA
    Inorg Chem; 2021 Sep; 60(18):14174-14189. PubMed ID: 34477373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruthenium(II) Phosphine/Mercapto Complexes: Their in Vitro Cytotoxicity Evaluation and Actions as Inhibitors of Topoisomerase and Proteasome Acting as Possible Triggers of Cell Death Induction.
    Ribeiro GH; Guedes APM; de Oliveira TD; de Correia CRSTB; Colina-Vegas L; Lima MA; Nóbrega JA; Cominetti MR; Rocha FV; Ferreira AG; Castellano EE; Teixeira FR; Batista AA
    Inorg Chem; 2020 Oct; 59(20):15004-15018. PubMed ID: 32997499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-mutagenic Ru(ii) complexes: cytotoxicity, topoisomerase IB inhibition, DNA and HSA binding.
    da Silva MM; de Camargo MS; Correa RS; Castelli S; De Grandis RA; Takarada JE; Varanda EA; Castellano EE; Deflon VM; Cominetti MR; Desideri A; Batista AA
    Dalton Trans; 2019 Oct; 48(39):14885-14897. PubMed ID: 31555783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic activity of Ru(II)/DPEPhos/N,S-mercapto complexes (DPEPhos = bis-[(2-diphenylphosphino)phenyl]ether).
    Grawe GF; Oliveira KM; Leite CM; de Oliveira TD; Costa AR; Moraes CAF; Honorato J; Cominetti MR; Castellano EE; Correa RS; Machado SP; Batista AA
    J Inorg Biochem; 2023 Jul; 244():112204. PubMed ID: 37004320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ru/Fe bimetallic complexes: Synthesis, characterization, cytotoxicity and study of their interactions with DNA/HSA and human topoisomerase IB.
    Takarada JE; Guedes APM; Correa RS; Silveira-Lacerda EP; Castelli S; Iacovelli F; Deflon VM; Batista AA; Desideri A
    Arch Biochem Biophys; 2017 Dec; 636():28-41. PubMed ID: 29107586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mononuclear η
    Kanyora AK; Omondi RO; Ongoma P; Omolo JO; Welsh A; Prince S; Gichumbi J; Mambanda A; Smith GS
    J Biol Inorg Chem; 2024 Mar; 29(2):251-264. PubMed ID: 38494554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapachol in the Design of a New Ruthenium(II)-Diphosphine Complex as a Promising Anticancer Metallodrug.
    Oliveira KM; Honorato J; Demidoff FC; Schultz MS; Netto CD; Cominetti MR; Correa RS; Batista AA
    J Inorg Biochem; 2021 Jan; 214():111289. PubMed ID: 33137682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
    Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
    Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel phosphine sulphide gold(i) complexes: topoisomerase I inhibitors and antiproliferative agents.
    Martín-Encinas E; Conejo-Rodríguez V; Miguel JA; Martínez-Ilarduya JM; Rubiales G; Knudsen BR; Palacios F; Alonso C
    Dalton Trans; 2020 Jun; 49(23):7852-7861. PubMed ID: 32463416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and anti-cancer activity of bis-amino-phosphine ligand and its ruthenium(II) complexes.
    Engelbrecht Z; Roberts KE; Hussan A; Amenuvor G; Cronjé MJ; Darkwa J; Makhubela BCE; Sitole L
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127492. PubMed ID: 32791194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Cytotoxicity against Breast Cancer Cells by Using Mixed-Ligand Ruthenium(II) Complexes of 2,2'-Bipyridine, Amino Acid, and Nitric Oxide Derivatives as Potential Anticancer Agents.
    Gaspari APS; da Silva RS; Carneiro ZA; de Carvalho MR; Carvalho I; Pernomian L; Ferreira LP; Ramos LCB; de Souza GA; Formiga ALB
    Anticancer Agents Med Chem; 2021; 21(12):1602-1611. PubMed ID: 33081686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic Ruthenium(II) Complexes Containing a Dangling Pyridine: Selectivity for Diseased Cells Mediated by pH-Dependent DNA Binding.
    Sangeetha S; Murali M
    Inorg Chem; 2022 Feb; 61(6):2864-2882. PubMed ID: 35099196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
    Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
    Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure elucidation {spectroscopic, single crystal X-ray diffraction and computational DFT studies} of new tailored benzenesulfonamide derived Schiff base copper(II) intercalating complexes: Comprehensive biological profile {DNA binding, pBR322 DNA cleavage, Topo I inhibition and cytotoxic activity}.
    Afsan Z; Roisnel T; Tabassum S; Arjmand F
    Bioorg Chem; 2020 Jan; 94():103427. PubMed ID: 31735357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Coordination Mode of Acylthiourea Ligands in Half-Sandwich Ru(II) Complexes and Their Cytotoxic Evaluation.
    Cunha BN; Luna-Dulcey L; Plutin AM; Silveira RG; Honorato J; Cairo RR; de Oliveira TD; Cominetti MR; Castellano EE; Batista AA
    Inorg Chem; 2020 Apr; 59(7):5072-5085. PubMed ID: 32208661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chiral ruthenium(II) anthraquinone complexes as dual inhibitors of topoisomerases I and II.
    Kou JF; Qian C; Wang JQ; Chen X; Wang LL; Chao H; Ji LN
    J Biol Inorg Chem; 2012 Jan; 17(1):81-96. PubMed ID: 21858685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
    de Camargo MS; De Grandis RA; da Silva MM; da Silva PB; Santoni MM; Eismann CE; Menegário AA; Cominetti MR; Zanelli CF; Pavan FR; Batista AA
    Biometals; 2019 Feb; 32(1):89-100. PubMed ID: 30506342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
    Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A
    Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic Ruthenium(II) Complexes of Pyrazolylbenzimidazole Ligands That Inhibit VEGFR2 Phosphorylation.
    Chakraborty A; Roy S; Chakraborty MP; Roy SS; Purkait K; Koley TS; Das R; Acharya M; Mukherjee A
    Inorg Chem; 2021 Dec; 60(23):18379-18394. PubMed ID: 34780170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of Ru(II) piano-stool complexes with chloroquine and chelating ligands against breast and lung tumor cells: Interactions with DNA and BSA.
    Colina-Vegas L; Villarreal W; Navarro M; de Oliveira CR; Graminha AE; Maia PIDS; Deflon VM; Ferreira AG; Cominetti MR; Batista AA
    J Inorg Biochem; 2015 Dec; 153():150-161. PubMed ID: 26277415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.